Last reviewed 2026-04-23 · How we verify

SHR-1701、CAPOX

SHR-1701 is a PD-L1 inhibitor combined with CAPOX chemotherapy (capecitabine and oxaliplatin) to enhance anti-tumor immunity while delivering cytotoxic chemotherapy.

SHR-1701 is a PD-L1 inhibitor combined with CAPOX chemotherapy (capecitabine and oxaliplatin) to enhance anti-tumor immunity while delivering cytotoxic chemotherapy. Used for Gastric cancer or gastroesophageal junction cancer (in combination with CAPOX), Colorectal cancer (in combination with CAPOX).

At a glance

Mechanism of action

SHR-1701 blocks the PD-L1 checkpoint, preventing tumor cells from suppressing T-cell responses, thereby restoring anti-tumor immunity. When combined with CAPOX chemotherapy, the regimen delivers both direct cytotoxic effects and enhanced immunological attack against cancer cells. This combination approach is designed to improve efficacy in solid tumors, particularly gastric and colorectal cancers.

Approved indications

• Gastric cancer or gastroesophageal junction cancer (in combination with CAPOX)
• Colorectal cancer (in combination with CAPOX)

Common side effects

• Nausea and vomiting
• Diarrhea
• Fatigue
• Immune-related adverse events (e.g., pneumonitis, hepatitis)
• Neutropenia
• Anemia

Key clinical trials

• Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer (PHASE2)
• SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis (PHASE2)
• PD1/TGFβ In Combination With EZH2 And Chemotherapy For First - Line Treatment Of Gastric Cancer (PHASE2)
• A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.